Research progress about the efficacy of cytochrome P450 2C19*17 variant to clopidogrel
10.13699/j.cnki.1001-6821.2015.07.027
- VernacularTitle:细胞色素 P4502 C19*17基因突变影响氯吡格雷作用的研究进展
- Author:
Yu-Hong ZENG
1
;
Guo-Ping YANG
;
Cheng-Xian GUO
;
Li-Ying GONG
Author Information
1. 中南大学湘雅三医院
- Keywords:
clopidogrel;
cytochrome P450 2 C19*17;
bleeding;
variant
- From:
The Chinese Journal of Clinical Pharmacology
2015;(7):577-579
- CountryChina
- Language:Chinese
-
Abstract:
Clopidogrel is one of the most commonly used anti -platelet drugs in clinical.But it shows the significant individual differences during effective anti-platelet therapy.The differences induced can′t be effective anti -platelet aggregate that caused cardiovascular ischemic events, or may enhanced the efficacy of clopidogrel and caused bleeding.The study found cytochrome P 450 2 C19*17 ( CYP2 C19*17 ) variant can enhance the activity of metabolizing enzymes , increasing the active metabolites exposed to clopidogrel , thereby enhanced the efficacy of clo-pidogrel.This article systematically summarizes domestic and foreign re-searches about the relationship of CYP2C19*17 variant and the efficacy of clopidogrel in order to provide some suggestions for personalized medi-cine.
